|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/24 | |
| A61K 39/395 | |||
| A61P 19/10 |
| (11) | Number of the document | 2245062 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09702831.0 |
| Date of filing the European patent application | 2009-01-15 | |
| (97) | Date of publication of the European application | 2010-11-03 |
| (45) | Date of publication and mention of the grant of the patent | 2012-04-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2009/031126 |
| Date | 2009-01-15 |
| (87) | Number | WO 2009/091905 |
| Date | 2009-07-23 |
| (30) | Number | Date | Country code |
| 21218 P | 2008-01-15 | US |
| (72) |
BEBBINGTON, Christopher R., US
YARRANTON, Geoffrey T., US
|
| (73) |
Kalobios Pharmaceuticals, Inc.,
260 East Grand Avenue, South San Francisco, CA 94080,
US
|
| (54) | METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST |
| METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST |